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Oral vitamin D supplementation induces
transcriptomic changes in rectal mucosa
that are linked to anti-tumour effects
P. G. Vaughan-Shaw1,2 , G. Grimes1,2, J. P. Blackmur1,2, M. Timofeeva3,4, M. Walker1,2, L. Y. Ooi1,5, Victoria Svinti1,2,
Kevin Donnelly1,2, F. V. N. Din1,2, S. M. Farrington1,2 and M. G. Dunlop1,2*
Abstract
Background: The risk for several common cancers is influenced by the transcriptomic landscape of the respective
tissue-of-origin. Vitamin D influences in vitro gene expression and cancer cell growth. We sought to determine
whether oral vitamin D induces beneficial gene expression effects in human rectal epithelium and identify
biomarkers of response.
Methods: Blood and rectal mucosa was sampled from 191 human subjects and mucosa gene expression (HT12)
correlated with plasma vitamin D (25-OHD) to identify differentially expressed genes. Fifty subjects were then
administered 3200IU/day oral vitamin D3 and matched blood/mucosa resampled after 12 weeks. Transcriptomic
changes (HT12/RNAseq) after supplementation were tested against the prioritised genes for gene-set and GO-
process enrichment. To identify blood biomarkers of mucosal response, we derived receiver-operator curves and C-
statistic (AUC) and tested biomarker reproducibility in an independent Supplementation Trial (BEST-D).
Results: Six hundred twenty-nine genes were associated with 25-OHD level (P < 0.01), highlighting 453 GO-term
processes (FDR<0.05). In the whole intervention cohort, vitamin D supplementation enriched the prioritised mucosal
gene-set (upregulated gene-set P < 1.0E−07; downregulated gene-set P < 2.6E−05) and corresponding GO terms
(P = 2.90E−02), highlighting gene expression patterns consistent with anti-tumour effects. However, only 9 individual
participants (18%) showed a significant response (NM gene-set enrichment P < 0.001) to supplementation. Expression
changes in HIPK2 and PPP1CC expression served as blood biomarkers of mucosal transcriptomic response (AUC=0.84
[95%CI 0.66–1.00]) and replicated in BEST-D trial subjects (HIPK2 AUC=0.83 [95%CI 0.77–0.89]; PPP1CC AUC=0.91 [95%CI
0.86–0.95]).
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Conclusions: Higher plasma 25-OHD correlates with rectal mucosa gene expression patterns consistent with anti-
tumour effects, and this beneficial signature is induced by short-term vitamin D supplementation. Heterogenous gene
expression responses to vitamin D may limit the ability of randomised trials to identify beneficial effects of
supplementation on CRC risk. However, in the current study blood expression changes in HIPK2 and PPP1CC identify
those participants with significant anti-tumour transcriptomic responses to supplementation in the rectum. These data
provide compelling rationale for a trial of vitamin D and CRC prevention using easily assayed blood gene expression
signatures as intermediate biomarkers of response.
Keywords: Vitamin D, Colorectal cancer, Gene expression, Biomarker
Background
Vitamin D deficiency is associated with the risk of sev-
eral common cancers, the strongest evidence supporting
a link between vitamin D and colorectal cancer [1, 2].
However, a causal association has yet to be convincingly
demonstrated, because the available observational evi-
dence may be participant to several potential con-
founders. Environmental risk factors associated with
CRC are also associated with vitamin D status (i.e. co-
causality; e.g. physical activity), while CRC or its treat-
ment may itself lower plasma vitamin D levels (i.e. re-
verse causation). However, a recent randomised-control
trial (RCT) reported an association between supplemen-
tation, vitamin D receptor genotype, and risk of colorec-
tal adenoma, supporting the premise that the beneficial
effect may be causal [3]. Meanwhile, vitamin D-related
genetic variation has been shown to influence the associ-
ation between 25-OHD level and CRC survival [4–6],
with a recent meta-analysis of RCT data strongly sup-
porting a causal effect for vitamin D supplementation on
CRC mortality [7, 8].
Differences in gene expression have been reported in
CRC and adenoma tissue relative to normal colorectal tis-
sue [9–12], with genes involved in metabolism, transcrip-
tion, and translation and cellular processes commonly
altered [13]. Recent transcriptome wide association studies
confirm the importance of gene expression in carcinogen-
esis [14, 15]. Vitamin D broadly influences gene expres-
sion through activation of the ligand-activated
transcription factor VDR, which has been shown to influ-
ence cancer cell growth in vitro [16]. Therefore, investiga-
tion of gene expression in the colorectum in the context
of vitamin D status or supplementation may provide fresh
insight into mechanisms underlying the relationship be-
tween CRC and vitamin D. Recent evidence suggests one
mechanism may be that 1,25-dihydroxyvitamin D3 modu-
lates immune and inflammatory pathway genes in large
bowel epithelium [17]. However, differential expression in
response to high dose 1,25-dihydroxyvitamin D3 may not
accurately reflect the relationship between vitamin D sta-
tus and gene expression at normal or low vitamin D levels,
or in response to regular vitamin D3, the most commonly
used vitamin D supplement.
We investigated whether circulating vitamin D con-
centration is associated with differential gene expression
in rectal normal mucosa using a 2-Phase approach with
validation of putative biomarkers in an independent
study dataset. We directly assayed total 25-OHD, which
reflects both dietary intake and skin synthesis of vitamin
D [18, 19] and investigated its relationship with gene ex-
pression in normal mucosa, assessed by microarray. In
the Phase 1 correlative study we sought to identify a
prioritised list of differentially expressed genes associated
with 25-OHD level. In Phase 2, we conducted a study in
human volunteers who were supplemented with oral
vitamin D to determine whether the corresponding tran-
scriptomic response was induced in vivo. Using blood
peripheral blood mononuclear cells (PBMC) transcrip-
tomic analysis, we also identified potential blood bio-
markers that indirectly indicate a beneficial response in
the host rectal mucosa.
Methods
Study population
Participants recruited to Phase 1 of the Scottish Vitamin
D study (see Additional file 1: Protocol) (n = 191) under-
went sampling of the blood and normal rectal mucosa
by rigid sigmoidoscopic biopsy. Eligibility criteria in-
cluded age over 16, ability to perform informed consent,
absence of bleeding risk (e.g. coagulopathy, anti-
coagulants) and absence of acute colorectal/ano-rectal
pathology (e.g. peritonitis, diverticulitis, recent colorectal
surgery, anal fissure). RNA was extracted for gene ex-
pression analysis from matched contemporaneous NM
and peripheral blood mononuclear cells (PBMCs).
Plasma was collected at the same time for vitamin D
analysis, and DNA was extracted from whole blood for
genotyping.
All eligible participants from Phase 1 were invited to
proceed to Phase 2 which was an intervention study.
Five of the 50 recruited participants to Phase 2 under-
went interval sampling before starting supplementation
to assess for longitudinal changes in expression before
treatment. All Phase 2 participants were then adminis-
tered vitamin D supplementation and underwent repeat
NM, PBMC, and 25-OHD sampling after 12 weeks’
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3200IU/day cholecalciferol (Fultium-D3) supplementa-
tion (Fig. 1). No vitamin D supplementation outside of
the study protocol was allowed, and concordance with
the treatment protocol was assessed through a dose
diary and pharmacy log of unused tablets (compliance of
98% of total doses taken achieved). Demographic and
clinical data were prospectively collected from patient
case notes.
Sample size considerations
There were no available published data on which to base
investigation of the sample size required to determine an
association between vitamin D status and global gene
expression in normal mucosa. Thus, a formal sample
size estimation was not possible.
Blood and mucosa sampling
Participants were sampled in outpatient clinic or during
minor surgical procedures. No participant received
cleansing oral mechanical bowel preparation. Blood was
sampled by standard venepuncture of a peripheral arm
vein, with plasma and PBMCs extracted (Additional file
2: Supplementary Methods [20–29]). A separate blood
sample was taken to allow extraction of blood leukocyte
DNA and genotyping of functionally relevant vitamin D
receptor (VDR) polymorphisms (rs1544410, rs10735810,
rs7975232, rs11568820 [26–28]) and vitamin D pathway
SNPs associated with 25-OHD level (rs2282679,
rs10741657, rs2228570, rs6013897 [25]). Normal rectal
mucosa (NM) was sampled at the same time via rigid
sigmoidoscopic rectal biopsy. NM and PBMC samples
were immediately placed in RNAlater and kept
immersed for 24–72 h prior to RNA extraction or stor-
age at −80°C.
Plasma vitamin D assay
All plasma samples were measured to a standard, vali-
dated, and published protocol by a single laboratory
[30]. Total 25-OHD was measured by liquid chromatog-
raphy tandem mass spectrometry.
Assessment of gene expression
RNA was extracted and purified from NM and blood
PBMC using a proprietary RNA extraction kit. Gene ex-
pression profiling was undertaken using the Illumina
HumanHT-12v4.0 Expression BeadChip Arrays and
IScan NO660 scanner, providing coverage of 47,231
transcripts and >31,000 annotated genes. For RNA se-
quencing, whole-genome transcriptomic patterns were
analysed on total RNA from selected normal mucosa
samples extracted as described above. RNA was se-
quenced on the Illumina HiSeq 2500 platform in “rapid
mode” with 150bp paired-end reads in a single batch.
Transcript indexing and quantification from RNA-seq
reads was performed using Salmon v1.1.0 [21].
Statistical analysis
All statistical analysis was undertaken in R [29]. In Phase
1, linear regression modelling was used to test associ-
ation between 25-OHD level and NM gene expression,
adjusting for age, gender, CRC status and anaesthetic
status (i.e. sampled under general anaesthetic). VDR
haplotype was included in a secondary model for a sub-
set of participants. Genes associated with 25-OHD level
at significance level P < 0.01 were termed the ‘candidate
gene-set’ and taken forward for testing in the interven-
tion dataset (Phase 2). In Phase 2, differences in 25-
OHD level before and after vitamin D supplementation
were investigated using paired Wilcoxon rank-sum test
and differential gene expression analysis in response to
vitamin D supplementation performed using the lmFit
and eBayes functions within the ‘limma’ package [31]
producing the intervention (Phase 2) dataset. Ranked
lists of differentially expressed genes were assessed for
functional relevance using the ‘GOrilla', Gene Ontology
enRIchment anaLysis and visuaLizAtion tool [32] and
Fig. 1 Summary of SCOVIDS study protocol. An unselected subset of Phase 1 participants (i.e. selection not based on 25-OHD or baseline gene
expression) proceeded to Phase 2 and were given 3200IU cholecalciferol per day. Of these, 5 participants were sampled 6 weeks after initial sampling
and without supplementation to provide a control dataset, after which they proceeded to 12 week’s supplementation and final sampling
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replicated using the gseGO function within the ‘cluster-
Profiler’ package in R [33]. Process ontologies were in-
vestigated using gene lists ranked by coefficient (Phase
1) or fold-change (Phase 2).
We tested the Phase 2 dataset (i.e. response to supple-
mentation) for enrichment of the Phase 1 candidate
gene-set and top-ranked GO terms. Directional gene-set
testing was performed in R, using the gene-setTest func-
tion in the ‘limma’ package [34]. We performed tech-
nical replication by performing gene-set enrichment
testing on differential expression data derived from
RNA-seq analysis of the same NM samples from the
intervention cohort.
To identify biomarkers of response, we performed
participant-level gene-set enrichment testing with a ‘re-
sponse’ to supplementation defined as enrichment (P < 0.001
given n = 50 subjects) of the candidate gene-set after supple-
mentation. Then, differentially expressed genes in the blood
between those with/without rectal NM response were tested
for enrichment of the candidate gene-set. Logistic regression
testing sought to identify potential blood biomarkers of re-
sponse and utility of blood biomarkers was calculated using
receiver operator curves and C statistic. Finally, we sought to
validate putative biomarkers of response in an independent
blood gene expression dataset derived from the ‘Biochemical
Efficacy and Safety Trial of Vitamin D’ (BEST-D) study [35]
(https://www.ebi.ac.uk/arrayexpress/files/E-MTAB-6246/).
Results
Mucosal gene expression signature associated with
higher 25-OHD level consistent with anti-tumour effects
In Phase 1, 191 participants underwent rectal mucosal
biopsy and blood sampling (Table 1). 25-OHD was
nominally associated with expression of 629 probes (P <
0.01), termed the ‘candidate gene-set’ (‘Gene-set discov-
ery’ Fig. 2).
No individual probe was significantly associated with
25-OHD after adjustment for genome-wide multiple
testing (Additional file 3: Table S2), yet the top 3 hits
have previous reported association with colorectal
tumourigenesis CNN1 [36], COX7A1 [37] and PIP5K1C
[38]. Gene ontology analysis demonstrated significant
enrichment of 453 processes (Additional file 3: Table S3)
with many highly relevant to carcinogenesis e.g. ‘regula-
tion of cell migration’ (FDR=7.55E-08), ‘regulation of
programmed cell death’ (FDR=5.38E-03) and ‘regulation
of cell differentiation’ (FDR=2.55E-05). Several genes
from the candidate gene-set with higher expression asso-
ciated with higher 25-OHD are included in enriched GO
ontology terms relevant to carcinogenesis and have re-
ported tumour suppressor activity (e.g. FOXOs, CAV1,
LRP1, Additional file 3: Tables S4, S5 [39–58]). This sug-
gests that the NM gene expression signature, i.e. Phase 1
‘candidate gene-set’, associated with higher 25-OHD
level is consistent with anti-tumour effects.
Oral vitamin D supplementation enriches anti-tumour
expression signature in normal rectal mucosa
In Phase 2, 50 participants were administered vitamin D
supplementation and underwent repeat sampling after
12-weeks. Post hoc analysis revealed age, gender and
baseline 25-OHD to be similar between Phase 1/2
participants (P > 0.05). Supplementation induced an in-
crease in plasma 25-OHD after 12 weeks (median
plasma 25-OHD before/after supplementation was
36nmol/l, 89nmol/l; P = 2.5E−09), with a suggestive






Age (median, range) 63 (24-89) years 66 (24-88) years
Gender (male) 101 (53%) 26 (52%)
Diagnosis
Pre-operative; colorectal cancer* 57 1
None (healthy) 63 20
Past medical history of CRC* 23 21
Minor anorectal pathology, no CRC† 45 7
Abdominal tumour (not colorectal) 3 1
Sampled under general anaesthetic 89 3
Median 25-OHD –Baseline 40 (IQR 37) nmol/l 36 (IQR 31) nmol/l
Median 25-OHD –After supplementation NA 89 (IQR 33.5) nmol/l
Ethnic background for Phase 1 participants were as follows: 183 European, 2 American, 3 African, 3 Asian. * Pre-operative patients had not undergone any neo-
adjuvant chemo/radiotherapy at time of sampling. Patients with past history of CRC were previously treated with curative resection +/- adjuvant chemotherapy
and no evidence of recurrence at time of recruitment. No significant differences in gene expression were identified according to participant diagnosis. † Full
diagnosis list given in Additional file 3: Table S1
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Fig. 2 Analysis flowchart and gene-set selection for biomarker assessment













































NM normal mucosa. P value given for directional gene-set enrichment test of whether Phase 1 candidate gene-set showed greater change after supplementation
when compared to randomly chosen genes. n = number of genes tested. Rectal response is defined by candidate gene-set enrichment in NM P < 0.001. To
explore the role of VDR genotype in modifying the association between 25-OHD and gene expression, VDR haplotypes were derived for the four genotyped VDR
polymorphisms, rs1544410, rs10735810, rs7975232, rs11568820, using BEAGLE software (version 3.3.2) with standard settings [59] and used as additional
covariates in the linear regression model in a subset of 125 participants, resulting in a smaller candidate gene-set which remained significantly enriched after
supplementation (P < 0.0001)
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association between genotype at two vitamin D pathway
SNPs (rs2282679, rs2228570) and 25-OHD fold-change
after supplementation (Additional file 3: Table S6).
No individual gene from the candidate gene-set
showed significant differential expression after adjust-
ment for multiple testing (Additional file 3: Table S7).
However, testing of the Phase 1 candidate gene-set
showed significant enrichment after supplementation
(upregulated gene-set P < 1.0E−07; downregulated gene-
set 2.8E−05, see ‘Gene-set testing’ Fig. 2, Table 2, Add-
itional file 3: Figure S1), confirmed in RNA-seq data.
Gene-set testing of a candidate gene-set from Phase 1
adjusted for VDR haplotypes, also showed significant en-
richment (P < 0.0001).
Enrichment of the candidate gene-set was not associ-
ated with 25-OHD response to supplementation, with
those with the lowest 25-OHD FCs still showing gene-
set enrichment (Additional file 3: Figure. S1). Mean-
while, there was no enrichment of the candidate gene-
set in interval NM samples taken before commencement
of supplementation indicating it is a treatment effect
(median interval 8 weeks, Additional file 3: Figure S1).
Of the 629 candidate genes associated with circulating
vitamin D in the Phase 1 gene-set, 55 had nominally sig-
nificant expression change after supplementation (P <
0.05). Concordance in direction of effect between the co-
efficient of association with plasma 25-OHD level and
expression change after supplementation was observed
in 49 of these (R0.93, P < 2.2E−16, Additional file 3:
Table S7), with these genes taken forward for biomarker
discovery (see ‘Biomarker discovery’ section Fig. 2).
GO term enrichment indicates modulation of anti-tumour
effects in normal mucosa by supplementation
Functional annotation of the intervention dataset gene
list identified 65 significantly enriched pathways after
supplementation, with many terms relevant to carcino-
genesis including ‘regulation of programmed cell death
(FDR=9.66E-03) and ‘regulation of cell migration’ (FDR=
7.83E−03) (Additional file 3: Table S8). Taken together,
genes in the top 50 GO terms from Phase 1 were signifi-
cantly enriched after supplementation (P = 2.90E−02).
Common processes across both the Phase 1 and Phase 2
datasets included terms relevant to carcinogenesis in-
cluding ‘regulation of programmed cell death’, ‘regula-
tion of cell migration’ (Additional file 3: Figure S2),
demonstrating that biologically relevant patterns of gene
expression changes associated with higher 25-OHD level
and consistent with anti-tumour effects could be
imparted by oral supplementation. Results from GOrilla
analysis were replicated using both DAVID and GSEA in
R, which confirmed enrichment of common processes
depicted in Additional file 3: Figure S2, and direction of
effect, with terms consistent with ‘anti-tumour’ effects
activated in relation to both higher 25-OHD and after
vitamin D supplementation.
Blood expression biomarkers identify participants with
gene expression response to supplementation
We identified 9 individual participants (18%) with a sig-
nificant response (i.e. candidate gene-set enrichment in
NM P < 0.001) to supplementation. Of the top 50
ranked GO terms from Phase 1, 43 were enriched in
these 9 participants after supplementation indicating a
biologically relevant NM gene expression response to
supplementation, which was absent in the remaining
participants (Additional file 3: Table S9). NM gene ex-
pression response was associated with an increased allele
risk score of the four functionally relevant VDR SNPs (p
= 0.006), but not with VDR gene expression, increased
25-OHD fold-change or baseline 25-OHD when adjust-
ing for multiple testing (Additional file 3: Table S10).
Changes in PBMC gene expression after supplementa-
tion reflected those in the rectum, with the Phase 1 can-
didate gene-set significantly enriched in the blood after
supplementation (Table 2). Moderate correlation be-
tween blood and rectum fold-change in the 49 genes
taken forward for biomarker discovery was seen (R=0.64,
P = 5.63E−06). When we compared PBMC gene expres-
sion after supplementation between those participants
with and without a rectal mucosal gene expression re-
sponse, the differentially expressed genes in PBMCs
were enriched for the candidate gene-set, indicating po-
tential blood biomarkers of mucosal response (Table 2,
see ‘Biomarker discovery’ section Fig. 2). Five genes
identified from the Phase 1 which were both differen-
tially expressed in NM after supplementation and also
differentially expressed in blood between participants
with and without a rectal response to supplementation
(SMEK2, HIPK2, PPP1C, DDR1 and SNX21), indicating
biomarker potential (Table 3). When the genes were
combined, a blood expression signature based on the
best derived cut-off showed strong utility in predicting
NM response (AUC=0.99, 95%CI 0.97–1.00, Additional
file 3: Table S11, Figure S3).
We then explored the value of these same genes as
blood biomarkers of the blood response to supplementa-
tion. The HIPK2 and PPP1CC genes (Table 3, Fig. 3)
demonstrated the best predictive utility in identifying
participants with response in both rectum (AUC=0.84,
95%CI 0.66–1.00) and blood (AUC=0.87, 95%CI 0.71–
1.00, Additional file 3: Table S11).
HIPK2 and PPP1CC are independent biomarkers of
expression response to supplementation in the BEST-D
trial expression dataset
In the BEST-D trial, 48/172 (28%) participants showed
significant enrichment of our Phase 1 candidate gene-
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set. HIPK2 expression increased with supplementation
in the BEST-D trial (FC=1.07, p = 0.002), with the in-
crease greatest in those with a blood response to supple-
mentation as defined by our candidate gene-set (FC=
1.34; P = 4.6E−13, Fig. 3) and a 1.36 fold-difference in
expression change after supplementation between those
with/without a response to our candidate gene-set (P =
8.48E−12, Table 3). In the current intervention study
(SCOVIDS), we observed an average HIPK2 FC=1.11 in
the blood, with 21 (47%) participants showing a
FC>1.19, the optimum threshold determined by AUC
calculations. In the BEST-D study, 63 (37%) participants
taking oral vitamin D supplementation showed a
FC>1.19 response, with this signature more prevalent in
those taking 4000IU per day (42%), suggesting a dose-
response. HIPK2 expression change showed utility in
identifying those with a response to our candidate gene-
set, AUC=0.83 (95%CI 0.77–0.89, Fig. 3) and when the
threshold from our study was used, HIPK2 FC>1.19
AUC=0.74 (95%CI 0.66–0.81, Additional file 3: Table
S11).
PPP1CC expression showed non-significant decrease
after supplementation in the BEST-D cohort overall, but
when the participants were stratified by blood response,
PPP1CC was seen to increase in those without blood re-
sponse (P = 0.0015, Fig. 3) and markedly decreased in
those with a blood response (FC=0.67; P = 5.9E−15).
There was a 0.61 fold-difference in PPP1CC expression
change between those with and without a response to
our candidate gene-set (P = 1.98E−17, Table 3). A total
of 47 (27%) participants had PPP1CC FC<0.76 after sup-
plementation, closely reflecting the 11 (26%) participants
in the current intervention study. Crucially, PPP1CC ex-
pression change after supplementation showed utility as
a biomarker of blood response to our candidate gene-
set, AUC=0.91 (95%CI=0.86−0.95, Fig. 3) and when
using the threshold from the SCOVIDs study, PPP1CC
FC<0.76 AUC=0.83 (95%CI 0.76−0.89, Additional file 3:
Table S11).
Discussion
This study reveals demonstrable differences in gene ex-
pression patterns in normal rectal mucosa correlated
with plasma 25-OHD level. These differences are con-
sistent with beneficial effects on processes relevant to
colorectal carcinogenesis. Furthermore, we show that
oral supplementation with vitamin D induces changes in
the prioritised gene list. This indicates that the beneficial
expression “signature” is not static, but rather can be
modified by oral vitamin D supplementation, at least
within the timescale tested here. Although we were not
able to directly test cancer endpoints, there is consider-
able published evidence supporting the premise that en-
richment of this favourable gene-set imparts anti-
tumour effects.
Homeodomain-interacting protein kinase 2 (HIPK2) is
a known tumour suppressor gene [60] and the Protein
Phosphatase 1 Catalytic Subunit Gamma gene
(PPP1CC), a published molecular marker of CRC [61].
We found expression changes in these genes in blood to
have predictive value in reflecting rectal mucosa
response to supplementation. Hence, these may have
utility as blood biomarkers of a beneficial epithelial re-
sponse to supplementation. In addition, the effect on
gene expression in blood PBMCs appears robust, since
we replicated the effect in a large, independent, expres-
sion dataset, namely the BEST-D trial in which subjects
were administered oral vitamin D supplementation
(2000/4000IU 12 months).
We devised a 2-Phase in vivo approach, firstly to iden-
tify differentially expressed genes in the rectal epithelium
associated with plasma 25-OHD and determine the GO
terms and processes linked to that prioritised gene list.
However, our ultimate aim was to establish whether
these transcriptomic responses could be recapitulated by
oral vitamin D supplementation, thereby demonstrating
a modifiable transcriptomic landscape. Many of the top-
ranked genes associated with higher 25-OHD level have
links with CRC, for instance CNN1 [36], COX7A1 [37],
Table 3 Genes prioritised from Phase 1 correlative dataset modified by supplementation in NM with evidence of potential












With vs. without response, Blood
Coeff. P value FC P value FC P value FC P value FC P value FC P value
SMEK2 −0.002 0.007 0.93 0.020 0.97 0.272 0.74 0.007 - - - -
HIPK2 0.004 0.006 1.17 0.016 1.11 0.068 1.46 0.014 1.07 0.002 1.36 8.47E−12
PPP1CC −0.002 0.007 0.93 0.020 0.91 0.006 0.82 0.047 0.96 0.14 0.61 1.98E−17
SNX21 0.004 0.003 1.07 0.047 0.99 0.750 1.26 0.039 1.01 0.27 1.04 0.02
DDR1 0.007 0.008 1.14 0.0008 1.03 0.572 0.72 0.040 1.02 0.03 1.04 0.08
NM normal mucosa, FC fold-change. Results from Phase 1 and Phase 2 analysis given. For Phase 1, coefficient given for association with 25-OHD level. For Phase 2,
fold-change and P value given for gene expression response to supplementation in NM and in the blood. In final column, blood expression fold-change difference
between participants with and without NM response to the candidate gene-set is given
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Fig. 3 Blood HIPK2 and PPP1CC expression before and after supplementation in SCOVIDS and BEST-D trial with ROC of biomarker utility. Response
defined as participant level gene-set enrichment to Phase 1 candidate gene-set from our SCOVIDS study after HIPK2, PPP1CC, SMEK2, DDR1 and
SNX21 excluded
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PEG3 [62], PIP5K1C [38], TAGLN [63] and DAAM2
[64]. Furthermore, we highlight a number of genes
within processes relevant to tumourigenesis which are
associated with 25-OHD level and influenced by supple-
mentation. The directions of effect of these genes were
consistent with tumour suppressor activity. Enrichment
of pathways involved in cell migration and cell death val-
idate published in vitro data which demonstrate vitamin
D-induced growth arrest and apoptosis of CRC cell lines,
modulation of the Wnt signalling pathway, DNA repair
and immunomodulation [16]. Published clinical data also
corroborate our current findings, for example Protiva
et al., reported upregulation of genes involved in cell ad-
hesion in response to 1,25(OH)2D3 [17], while Bostick,
reported increased cell differentiation and apoptosis in
the normal human colorectal epithelium [65]. Taken to-
gether, these data suggest possible mechanisms under-
lying the widely reported link between vitamin D
deficiency and increased CRC risk [1, 2]. It also might
explain the recently reported beneficial impact of sup-
plementation on CRC survival outcomes [8].
Despite compelling published observational and pre-
clinical data, the link between vitamin D and risk of can-
cer and several other traits remains controversial. In-
deed, several large intervention trials have shown no
benefit on cancer endpoints (VITAL Trial [66], Vitamin
D Assessment (ViDA) study [67, 68] and Baron et al.
[69]). However, participants in these trials were predom-
inantly sufficient for vitamin D at the trial outset,
thereby potentially blunting beneficial effects [70]. We
have previously rehearsed potential reasons why previ-
ous study designs might have failed to detect real effects
[70]. To counter potential confounding effects, we con-
ducted a Mendelian randomisation study but this also
did not demonstrate a beneficial effect of circulating
vitamin D on CRC risk. However, available genetic in-
strumental variables are weak and explain only a small
portion of variance of 25OHD levels [71, 72].
In this study, 18% of participants receiving vitamin D
supplementation exhibited a response in the colorectal
epithelium (the putative target tissue). Unmeasured vari-
ables may account for the marked inter-individual vari-
ation in response including ethnic or genetic background,
dietary, lifestyle, pharmacological (e.g. concurrent medica-
tion) or pathological effects (e.g. unknown viral infection
during course of supplementation). Variation in the activ-
ity of the vitamin D enzymes or carriers (e.g. CYP24A1,
GC and CYP27B1 undetected in the current dataset) may
impact responses in the mucosa relative to 25-OHD
change, and we noted differential CYP2R1 change in the
rectum after supplementation between those with/without
a response to our candidate gene-set (FC 0.80 vs. 1.04, P =
0.007). Irrespective of the cause of inter-individual vari-
ation in response, if our hypothesis holds that expression
changes translate to cancer endpoints, this low response
rate would adversely impact on statistical power of trials
conducted to date which have tested the effect of vitamin
D supplementation on clinical endpoints. Such trials rou-
tinely perform subgroup analyses based on change in cir-
culating 25-OHD level, yet the current study reveals poor
correlation between plasma level and mucosal gene ex-
pression changes, suggesting non-linear responses to vita-
min D may introduce further heterogeneity to clinical
endpoints. Future work, including GWAS and machine
learning approaches will aim to define whether ‘response’
can be determined at baseline is required.
Crucially, we have identified blood biomarkers that re-
liably identify participants who respond to vitamin D
supplementation by inducing gene expression changes in
the target tissue. The value of these biomarkers is repli-
cated in a larger independent expression dataset. Further
work is required to assess the utility of respective blood
protein assays (e.g. ELISA) and reproducibility of these
blood biomarkers in identifying mucosal response across
a larger cohort. Nevertheless, these exciting and novel
findings provide rationale for a trial of vitamin D and
CRC prevention using easily assayed blood gene expres-
sion signatures as intermediate biomarkers of response.
Whilst the 2-Phase design of an intervention study in-
formed by our correlative dataset has many positive at-
tributes, the study has a number of limitations. First, the
low median level of 25-OHD and narrow positively
skewed distribution of 25-OHD in the Phase 1 cohort
may have masked some true associations between vita-
min D level and gene expression. Failure to identify indi-
vidual gene significance after adjustment for genome-
wide multiple testing may also indicate inadequate sam-
ple size, physiological autoregulation maintaining con-
stant gene expression despite differences in circulating
25-OHD, differences between plasma and rectal mucosa
concentrations of 25-OHD or 1,25-OHD [73] or hetero-
geneity in cell type in sampled mucosal tissue.
This intervention study is larger than many published
studies of gene expression and vitamin D supplementation
[17, 74–77], yet may still have limited power to achieve in-
dividual gene significance. Phase 2 participants were re-
cruited as a subset of the Phase 1 cohort, which may
influence gene-set enrichment test results. However, we
did not select those who received supplementation based
on 25-OHD level or baseline gene expression, which could
have led to overfitting of the data, but instead took an un-
selected group. If anything, this approach could blunt the
observed effect of supplementation, as mucosal response
to supplementation may be capped in those with specific
25-OHD or favorable patterns of gene expression at base-
line. Despite this, we observed significant enrichment of
the candidate gene-set derived in Phase 1 in those
receiving supplementation. Unmeasured variation in
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environmental exposures (e.g. diet or UVB exposure) may
have influenced responses, which should be accurately de-
tailed in future studies of vitamin D supplementation.
Sampling of rectal mucosa but not colonic mucosa
avoided the use of cleansing bowel laxatives which may in-
fluence gene expression [78], yet limits the generalisability
of our findings to more proximal colonic mucosa. Sam-
pling after 12 weeks of supplementation may not ad-
equately capture early or later gene expression changes
yet more frequent or delayed sampling would provide
additional practical and ethical challenges. Finally, we rec-
ognise responses to vitamin D supplementation and the
biomarker utility of HIPK2 and PPP1CC require further
mechanistic study (e.g. protein expression) to validate and
expand these findings towards a fuller understanding of
both biological mechanisms and biomarker potential.
Conclusions
In conclusion, we report for the first time patterns of
gene expression and functional pathways in the normal
rectal mucosa that are associated with circulating plasma
vitamin D level. Oral vitamin D supplementation in-
duces transcriptomic changes consistent with beneficial
anti-tumour effects. Blood leukocyte expression of
HIPK2 and PPP1CC predicted well those participants
with the greatest expression response following supple-
mentation. Whilst further replication in a separate co-
hort is desirable, these data provide compelling rationale
for a trial of vitamin D and CRC prevention using easily
assayed blood gene expression signatures as intermediate
biomarkers of response.
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